Cargando…
Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus for In Vitro and In Vivo Applications
Available treatments for hepatitis B can control the virus but are rarely curative. This led to a global initiative to design new curative therapies for the 257 million patients affected. Discovery and development of these new therapies is contingent upon functional in vitro and in vivo hepatitis B...
Autores principales: | Wettengel, Jochen M., Linden, Bianca, Esser, Knud, Laue, Michael, Burwitz, Benjamin J., Protzer, Ulrike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402639/ https://www.ncbi.nlm.nih.gov/pubmed/34452368 http://dx.doi.org/10.3390/v13081503 |
Ejemplares similares
-
Innovative HBV Animal Models Based on the Entry Receptor NTCP
por: Wettengel, Jochen M., et al.
Publicado: (2020) -
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy
por: van Vloten, Jacob P., et al.
Publicado: (2021) -
Concentration of Na(+)-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus
por: Oswald, Andreas, et al.
Publicado: (2021) -
Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro
por: Xia, Yuchen, et al.
Publicado: (2017) -
Rapid, Refined, and Robust Method for Expression, Purification, and Characterization of Recombinant Human Amyloid beta 1-42
por: Prakash, Priya, et al.
Publicado: (2019)